Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI-551 + MEDI0680
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MEDI-551 + MEDI0680 is a combination regimen of two monoclonal antibodies developed by MedImmune for use primarily in patients with relapsed or refractory aggressive B-cell lymphomas. **MEDI-551** (inebilizumab) is an afucosylated humanized IgG1 kappa monoclonal antibody targeting CD19 on B cells, designed to induce antibody-dependent cellular cytotoxicity (ADCC) leading to B-cell depletion. **MEDI0680** (AMP-514) is a humanized IgG4 kappa monoclonal antibody that blocks the PD-1 immune checkpoint on T cells, enhancing anti-tumor immune responses through immunomodulation. This combination aims to link the direct cytotoxic effect of B-cell depletion by MEDI-551 with immune response augmentation from PD-1 inhibition by MEDI0680, potentially increasing anti-lymphoma activity and offering patients an alternative to chemotherapy[1][4][5][7].
- Other names
- inebilizumab + MEDI0680
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on MEDI-551 + MEDI0680.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI-551 + MEDI0680.